Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yasushi Okoshi

Showing results (31-40 of 36) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 36 results.
Journal of Thrombosis and Thrombolysis|May 21, 2013
Prednisone versus high-dose dexamethasone for untreated primary immune thrombocytopenia. A retrospective study of the Japan Hematology & Oncology Clinical Study GroupKana Sakamoto, Hideki Nakasone, Shigeharu Tsurumi, et al.
American Journal of Hematology|March 2, 2013
In vivo T-cell depletion with alemtuzumab in allogeneic hematopoietic stem cell transplantation: Combined results of two studies on aplastic anemia and HLA-mismatched haploidentical transplantationYoshinobu Kanda, Kumi Oshima, Shinichi Kako, et al.
Acta Haematologica|April 15, 2015
Measurement of Proteasome Activity in Peripheral Blood Mononuclear Cells as an Indicator of Susceptibility to Bortezomib-Induced Severe Neurological Adverse Events in Patients with Multiple MyelomaYukiko Cho, Mitsuo Hori, Yasushi Okoshi, et al.
International Journal of Hematology|April 28, 2011
Adherence to the standard dose of imatinib, rather than dose adjustment based on its plasma concentration, is critical to achieve a deep molecular response in patients with chronic myeloid leukemiaChikashi Yoshida, Takuya Komeno, Mitsuo Hori, et al.
Haematologica|July 17, 2010
Prognostic factors and outcomes of adult patients with acute myeloid leukemia after first relapseSaiko Kurosawa, Takuhiro Yamaguchi, Shuichi Miyawaki, et al.
Acta Haematologica|February 7, 2019
Efficacy and Safety of a Weekly Cyclophosphamide-Bortezomib-Dexamethasone Regimen as Induction Therapy Prior to Autologous Stem Cell Transplantation in Japanese Patients with Newly Diagnosed Multiple Myeloma: A Phase 2 Multicenter TrialKeisuke Tanaka, Shigeo Toyota, Megumi Akiyama, et al.
Pageof 4

Showing results (31-40 of 36) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 36 results.
Journal of Thrombosis and Thrombolysis|May 21, 2013
Prednisone versus high-dose dexamethasone for untreated primary immune thrombocytopenia. A retrospective study of the Japan Hematology & Oncology Clinical Study GroupKana Sakamoto, Hideki Nakasone, Shigeharu Tsurumi, et al.
American Journal of Hematology|March 2, 2013
In vivo T-cell depletion with alemtuzumab in allogeneic hematopoietic stem cell transplantation: Combined results of two studies on aplastic anemia and HLA-mismatched haploidentical transplantationYoshinobu Kanda, Kumi Oshima, Shinichi Kako, et al.
Acta Haematologica|April 15, 2015
Measurement of Proteasome Activity in Peripheral Blood Mononuclear Cells as an Indicator of Susceptibility to Bortezomib-Induced Severe Neurological Adverse Events in Patients with Multiple MyelomaYukiko Cho, Mitsuo Hori, Yasushi Okoshi, et al.
International Journal of Hematology|April 28, 2011
Adherence to the standard dose of imatinib, rather than dose adjustment based on its plasma concentration, is critical to achieve a deep molecular response in patients with chronic myeloid leukemiaChikashi Yoshida, Takuya Komeno, Mitsuo Hori, et al.
Haematologica|July 17, 2010
Prognostic factors and outcomes of adult patients with acute myeloid leukemia after first relapseSaiko Kurosawa, Takuhiro Yamaguchi, Shuichi Miyawaki, et al.
Acta Haematologica|February 7, 2019
Efficacy and Safety of a Weekly Cyclophosphamide-Bortezomib-Dexamethasone Regimen as Induction Therapy Prior to Autologous Stem Cell Transplantation in Japanese Patients with Newly Diagnosed Multiple Myeloma: A Phase 2 Multicenter TrialKeisuke Tanaka, Shigeo Toyota, Megumi Akiyama, et al.
Pageof 4